Summit Therapeutics Inc. — Director's Dealing 2024

Sep 13, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-09-11

Reporting Person: Soni Manmeet Singh (Director, COO and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-11	Common Stock	A	44052	$22.70	Acquired	3020242	Direct

Footnotes

F1: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024.